日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration

Faricimab治疗新生血管性年龄相关性黄斑变性可快速消除积液并持久有效

Pitcher, John D 3rd; Koh, Adrian Hock Chuan; Tan, Colin S; Vakharia, Priya; Dagincourt, Nicholas; Patel, Shriji; Yang, Ming; Margaron, Philippe; Gallego-Pinazo, Roberto

Reduction in Pigment Epithelial Detachment Thickness with Faricimab versus Aflibercept 2 mg during Head-to-Head Dosing in TENAYA/LUCERNE

在TENAYA/LUCERNE研究中,法瑞西单抗与阿柏西普2 mg头对头给药比较显示,色素上皮脱离厚度降低。

Lim, Jennifer I; Ambresin, Aude; Avery, Robert L; Chaikitmongkol, Voraporn; Eter, Nicole; Gomi, Fumi; Khanani, Arshad M; London, Nikolas J S; Harrell, Emma; Margaron, Philippe; Patel, Shriji; Souverain, Audrey; Yang, Ming; Lai, Timothy Y Y

Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases

越来越多的临床证据表明,法瑞西单抗阻断血管紧张素-2和血管内皮生长因子-A在视网膜疾病中具有双重作用

Chaudhary, Varun; Mar, Florie; Amador, Manuel J; Chang, Andrew; Gibson, Kara; Joussen, Antonia M; Kim, Judy E; Lee, Junyeop; Margaron, Philippe; Saffar, Insaf; Wong, David; Wykoff, Charles; Sadda, Srinivas

Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE)

信息图:玻璃体内注射法瑞西单抗治疗新生血管性年龄相关性黄斑变性(治疗和延长给药方案,最长 16 周)的 2 年疗效、持久性和安全性(TENAYA 和 LUCERNE 的汇总结果)

Wijesingha, Naomi; Kotecha, Aachal; Margaron, Philippe; Sivaprasad, Sobha

Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes

Faricimab治疗新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿:从临床前研究到3期临床试验结果

Agostini, Hansjürgen; Abreu, Francis; Baumal, Caroline R; Chang, Dolly S; G Csaky, Karl; Demetriades, Anna M; Kodjikian, Laurent; Lim, Jennifer I; Margaron, Philippe; Monés, Jordi M; Peto, Tunde; Ricci, Federico; Rüth, Matthias; Singh, Rishi P; Stoilov, Ivaylo; Swaminathan, Balakumar; Willis, Jeffrey R; Westenskow, Peter D

Baseline characteristics associated with the first year treatment interval of intravitreal faricimab in neovascular age-related macular degeneration (nAMD)

新生血管性年龄相关性黄斑变性(nAMD)患者接受玻璃体内注射法瑞西单抗治疗第一年期间的基线特征

Shah, Parth; Rafijah, Neala; Tang, Yannan; Sivaprasad, Sobha; Mathis, Thibaud; Margaron, Philippe; Kotecha, Aachal

Evolution of Polypoidal Lesions after Treatment of Polypoidal Choroidal Vasculopathy

息肉状脉络膜血管病治疗后息肉状病变的演变

Tan, Colin S; Lim, Louis W; Margaron, Philippe

Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial

雷珠单抗联合或不联合维替泊芬光动力疗法治疗息肉状脉络膜血管病变的比较:EVEREST II 随机临床试验

Lim, Tock H; Lai, Timothy Y Y; Takahashi, Kanji; Wong, Tien Y; Chen, Lee-Jen; Ruamviboonsuk, Paisan; Tan, Colin S; Lee, Won Ki; Cheung, Chui Ming Gemmy; Ngah, Nor Fariza; Patalauskaite, Ramune; Margaron, Philippe; Koh, Adrian

Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study

功能性标准与功能性和解剖学标准指导的雷珠单抗治疗新生血管性年龄相关性黄斑变性患者的比较——来自随机、IIIb期OCTAVE研究的结果

Staurenghi, Giovanni; Garweg, Justus G; Gerendas, Bianca S; Macfadden, Wayne; Gekkiev, Boris; Margaron, Philippe; Dunger-Baldauf, Cornelia; Kolar, Petr

MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration

MACUSTAR:中度年龄相关性黄斑变性功能、结构和患者报告终点的开发和临床验证

Finger, Robert P; Schmitz-Valckenberg, Steffen; Schmid, Matthias; Rubin, Gary S; Dunbar, Hannah; Tufail, Adnan; Crabb, David P; Binns, Alison; Sánchez, Clara I; Margaron, Philippe; Normand, Guillaume; Durbin, Mary K; Luhmann, Ulrich F O; Zamiri, Parisa; Cunha-Vaz, José; Asmus, Friedrich; Holz, Frank G